Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer

Basit Öğe Kaydı
dc.authorscopusid57188676101
dc.authorscopusid57190121337
dc.authorscopusid57226307575
dc.authorscopusid57216852198
dc.authorscopusid6603166584
dc.authorscopusid57204771705
dc.authorscopusid59125368500
dc.contributor.authorKutlu Y.
dc.contributor.authorCekin R.
dc.contributor.authorAydin S.G.
dc.contributor.authorShbair A.T.M.
dc.contributor.authorBilici A.
dc.contributor.authorArici S.
dc.contributor.authorOven B.B.
dc.date.accessioned2024-06-12T10:25:00Z
dc.date.available2024-06-12T10:25:00Z
dc.date.issued2024
dc.description.abstractLoss of human epidermal growth factor receptor 2 (HER2) expression can be seen in almost 25–30 % patients after HER2 receptor directed neoadjuvant treatment. These patients have unclear clinical outcomes in previous studies. We aimed to investigate the importance of HER2 loss, additionally with predictive factors for the loss of HER2. This was a retrospective and multicenter study that included 272 HER2-positive BC patients with no pathological complete response who received neoadjuvant chemotherapy plus HER2-targeted treatments. The factors that may affect the loss of HER2 detected by immunohistochemistry(IHC) and the association with survival were analyzed.The rate of HER2 loss after neoadjuvant treatments(NAT) was 27.9 % (n = 76). Disease recurrence was observed in 18(23.7 %) patients with HER2 loss, while it was detected in 62 (31.7 %) patients without HER2 loss(p = 0.23). Pre and post-NAT ER status, and post-NAT ki-67 status had a significant impact on disease-free survival(DFS) (p = 0.0012, p = 0.004, and p = 0.04, respectively).There were no significant association between DFS and loss of HER2 (p = 0.64) and dual anti-HER2 blockade (p = 0.21). Pre-NAT clinical stage (HR:1.65 p = 0.013), post-NAT LN status (HR:3.18, p = 0.02) and pre-NAT ER status (HR:0.24, p = 0.041) were significant independent prognostic factors for DFS while post-NAT residual disease in axillar tissue was an independent prognostic factor for OS (HR:1.54 p = 0.019). Moreover, age (<40 years vs ?40 years) (p = 0.031) and tumor grade (p = 0.004) were predictive factors for HER2 loss. Our results showed that HER2 loss did not affect survivals. However, young age and being high grade tumor may predict HER2 loss. © 2024 Elsevier Inc.en_US
dc.identifier.doi10.1016/j.currproblcancer.2024.101102
dc.identifier.issn0147-0272
dc.identifier.pmid38735211en_US
dc.identifier.scopus2-s2.0-85193027238en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.currproblcancer.2024.101102
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16144
dc.identifier.volume50en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofCurrent Problems in Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Cancer; Disease-Free Survival; Her2 Expression Loss; Neoadjuvant Treatmenten_US
dc.subjectCyclophosphamide; Docetaxel; Doxorubicin; Epidermal Growth Factor Receptor 2; Epirubicin; Estrogen Receptor; Ki 67 Antigen; Paclitaxel; Pertuzumab; Progesterone Receptor; Taxane Derivative; Trastuzumab; Adult; Advanced Breast Cancer; Aged; Article; Cancer Grading; Cancer Staging; Clinical Outcome; Disease Free Survival; Female; Fluorescence In Situ Hybridization; Follow Up; Human; Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer; Human Tissue; Immunohistochemistry; Loading Drug Dose; Major Clinical Study; Minimal Residual Disease; Multiple Cycle Treatment; Multivariate Analysis; Neoadjuvant Chemotherapy; Neoadjuvant Therapy; Overall Survival; Recurrent Disease; Retrospective Study; Tumor Volume; Univariate Analysisen_US
dc.titlePrognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu